Pyxis Oncology, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Pyxis Oncology, Inc. (PYXS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 22.79 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 23.46M shares, a 8.15% increase year-over-year.
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 21.69M shares, a 62.70% increase year-over-year.
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 13.33M shares, a 4.98% increase year-over-year.
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 12.70M shares, a 25.24% increase year-over-year.
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 19.85M shares, a 10.00% increase from fiscal 2024.
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 18.05M shares, a 47.97% increase from fiscal 2023.
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 12.20M shares, a 11.20% increase from fiscal 2022.
- Pyxis Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 10.97M shares, a 32.74% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 22.79M shares 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | 23.46M shares 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | 19.85M shares 10-K · filed 2026-03-23 | |||||||
| 2025-09-30 | 21.17M shares 10-Q · filed 2025-11-03 | |||||||
| 2025-06-30 | 21.30M shares 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | 21.69M shares 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | 18.05M shares 10-K · filed 2026-03-23 | |||||||
| 2024-09-30 | 13.09M shares 10-Q · filed 2025-11-03 | |||||||
| 2024-06-30 | 13.21M shares 10-Q · filed 2025-08-14 | |||||||
| 2024-03-31 | 13.33M shares 10-Q · filed 2025-05-15 | |||||||
| 2023-12-31 | 12.20M shares 10-K · filed 2025-03-18 | 12.20M shares 10-K · filed 2024-03-21 | ||||||
| 2023-09-30 | 12.78M shares 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | 11.23M shares 10-Q · filed 2024-08-14 | |||||||
| 2023-03-31 | 12.70M shares 10-Q · filed 2024-05-14 | 13.16M shares 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | 10.97M shares 10-K · filed 2024-03-21 | 11.19M shares 10-K · filed 2023-03-22 | ||||||
| 2022-09-30 | 11.08M shares 10-Q · filed 2023-11-07 | 10.97M shares 10-Q · filed 2022-11-01 | ||||||
| 2022-06-30 | 9.78M shares 10-Q · filed 2023-08-11 | 9.67M shares 10-Q · filed 2022-08-15 | ||||||
| 2022-03-31 | 10.14M shares 10-Q · filed 2023-05-11 | 9.81M shares 10-Q · filed 2022-05-13 | ||||||
| 2021-12-31 | 8.26M shares 10-K · filed 2023-03-22 | 6.55M shares 10-K · filed 2022-03-29 | ||||||
| 2021-09-30 | 28.42M shares 10-Q · filed 2022-11-01 | |||||||
| 2021-06-30 | 24.26M shares 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | 24.37M shares 10-Q · filed 2022-05-13 | |||||||
| 2020-12-31 | 4.68M shares 10-K · filed 2022-03-29 | |||||||
| 2020-09-30 | 4.87M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |